about
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivoT-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivoT-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancerPolymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitroDual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivoDual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroPolymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomasSacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivoCervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
P50
Q27853078-0C346EA8-2E09-4F5C-865C-57108D3064D1Q34729807-99A63BA3-C13C-4354-A157-F24EE67BFE6EQ34998509-A05BD539-8B82-4342-9CE1-22A23D6D5B0CQ35007586-9BECE6E4-690C-4DC0-8D06-46CC810AF17AQ35027806-7995593F-7CA6-4F89-9CE9-F59F40DE5FA9Q35659378-7A5F56A5-B09D-4085-BFBC-A31346DBDEE1Q35748591-D28B3782-37E0-4318-A223-A6683268810CQ36103790-1AB02122-775F-46C9-B3A7-33D89E0CF57CQ36171935-CFEE9813-02DE-4F50-ADC1-A74332F160B0Q36258125-613AAFDF-1A7D-4370-B8AB-25597FB4D76EQ36295013-72E3FE5B-2300-4421-88ED-BE5BF81A26B3Q36421292-740CB9FE-593B-4987-8BE2-5DB047BB45B8Q37151091-DBF35727-1FC2-4F95-B278-D6C0D9322CE4Q38726540-9CE886E4-F6E5-4B88-839C-920A7BB602CEQ38766901-2F039EEE-0497-4828-9E38-469F6FEA2284Q38911022-6B7FF03C-1792-4B21-AD21-868FBE8C9046Q47104826-ECD2AF3E-6281-4AEF-95DF-10277E637818Q86837798-43ACD7D1-7A6F-4349-B1BE-25ACC1FD853AQ92350174-5090ECEE-AD46-4875-A415-C8378056016EQ92860703-C691E524-49E5-49C3-B2EA-E738448146EA
P50
description
investigador
@es
researcher
@en
name
Elena Bonazzoli
@en
type
label
Elena Bonazzoli
@en
prefLabel
Elena Bonazzoli
@en
P31
P496
0000-0003-2024-8102